{"disease":{"id":"childhood-absence-epilepsy","name":"Childhood absence epilepsy","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"prenderol","indication_name":"Childhood absence epilepsy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"2,2-Diethyl-1,3-Propanediol","generic_name":"prenderol","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"prenderol","quality_score":null,"revenue":null,"mechanism":"Prenderol works by modulating the activity of certain neurotransmitters in the brain to reduce seizure frequency."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04666610","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":153,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT06315322","title":"A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT05109234","title":"A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT06093490","title":"Detecting Absence Seizures Using Hyperventilation and Eye Movement Recordings","phase":"","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Eysz, Inc.","has_results":false},{"nct_id":"NCT06310772","title":"Assessing Comorbidities in Epilepsy Using Eye Movement Recordings","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Eysz, Inc.","has_results":false},{"nct_id":"NCT03336242","title":"Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Radius Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03355300","title":"Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Radius Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06153186","title":"Flunarizine for Treatment Resistant Absence Epilepsy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT03676543","title":"Mutual Interactions Between Absence Epilepsy Seizures and the Integration of Sensory Stimuli","phase":"NA","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}